ClinicalTrials.gg

Program

torvutatug samrotecan

Also written as “Torvutatug samrotecan” and “AZD5335”.

Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms, led by AstraZeneca.

Furthest: phase 3, since Oct 16, 20255 company-led studies, 5 open or runningNext primary completion: Oct 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca55 open or runningphase 3since Oct 16, 2025Feb 21, 2023Oct 15, 2027phase 1 · NCT07402915
  • Named in AstraZeneca’s own pipeline as torvutatug samrotecan, phase 3, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 21, 2023First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT05797168 · 622 planned · United States, Australia, Canada and more
  2. Oct 16, 2025Phase 3 study in Carcinoma, Ovarian EpithelialNCT07218809 · 1,100 planned · United States, Australia, Belgium and more
  3. Jan 23, 2026Phase 1 study in Fallopian Tube NeoplasmsNCT07402915 · 32 planned · Georgia, Ireland, Portugal and more
  4. Sep 7, 20262 phase 3 studiesNCT07816666, NCT07851025

Ahead

  1. Oct 15, 2027Primary completion: phase 1 study in Fallopian Tube NeoplasmsNCT07402915
  2. Aug 4, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT05797168
  3. Sep 29, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07816666
  4. Nov 17, 2028Primary completion: phase 3 study in Carcinoma, Ovarian EpithelialNCT07218809

TargetBeta

“An antibody-drug conjugate (ADC) composed of torvutatug, a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) conjugated to samrotecan, a linker conjugated to exatecan, with potential antineoplastic activity. Upon administration of torvutatug samrotecan, the antibody mo…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of torvutatug, a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) ”NCIt, by rule

Other programs on FOLR1

ProgramCompanyFurthest phaseStudies
mirvetuximab soravtansineruleAbbViephase 315
rinatabart sesutecanruleGenmabphase 39
sofetabart mipitecanEli Lillyphase 32
opugotamig olatansineAbbViephase 22
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901AbbViephase 11
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleteneoseven-incphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07851025Carcinoma, Ovarian Epithelial · United States, Argentina, Australia and more3RecruitingJun 28, 2030950
NCT07816666Ovarian Neoplasms · United States, Australia, Brazil and more3RecruitingSep 29, 2028600
NCT07402915Fallopian Tube Neoplasms · Georgia, Ireland, Portugal and more1RecruitingOct 15, 202732
NCT07218809Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more3RecruitingNov 17, 20281,100
NCT05797168Ovarian Neoplasms · United States, Australia, Canada and more2RecruitingAug 4, 2028622

How it is read

Names in the registry

  • “Torvutatug samrotecan”, 3 entries
  • “AZD5335”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.